AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

Samit Hirawat So for -- as I said earlier, for both of the studies, so CC-220, or iberdomide, we're looking at the readout of that fourth line plus population data within this year.

Samit Hirawat: Thank you for the question. Obviously, we’re looking forward to seeing the data for Opdualag, a randomized Phase 2 study looking at the combination of Opdivo relatlimab plus ...

According to a recent SEC filing, Hirawat purchased 1,823 shares of common stock at a price of $54.84 per share on February 14, 2025. This transaction amounted to a total value of $99,999.

For the biopharma industry, 2020 was many things, but for Samit Hirawat, M.D., chief medical officer of Bristol Myers Squibb, three things stand out: collaboration, adaptation and evolution.

Samit Hirawat So, yes. And I think – look, I don’t know whose excitement you were talking about, but we have a – and the data that continues to evolve increases our excitement.